Pharmacotherapy of comorbid mood, anxiety, and substance use disorders

被引：29
|
作者：
Brady, KT [1 ]
Verduin, ML [1 ]
机构：
[1] Med Univ S Carolina, Inst Psychiat, Charleston, SC 29425 USA
来源：
SUBSTANCE USE & MISUSE | 2005年 / 40卷 / 13-14期
关键词：
substance use; mood disorders; anxiety disorders; depression; bipolar disorder; panic disorder; post-traumatic stress disorder; obsessive compulsive disorder; social phobia; alcohol; cocaine; marijuana; opiates;
D O I：
10.1080/10826080500294924
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
Mood and anxiety disorders commonly co-occur with substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed.
引用
收藏
页码：2021 / 2041
页数：21
相关论文
共 50 条
  • [31] Evaluation of an integrated group cognitive-behavioral treatment for comorbid mood, anxiety, and substance use disorders: A pilot study
    Milosevic, Irena
    Chudzik, Susan M.
    Boyd, Susan
    McCabe, Randi E.
    JOURNAL OF ANXIETY DISORDERS, 2017, 46 : 85 - 100
  • [32] Chronic pain and comorbid mood and substance use disorders: A biopsychosocial treatment approach
    Cheatle M.D.
    Gallagher R.M.
    Current Psychiatry Reports, 2006, 8 (5) : 371 - 376
  • [33] Secular trends in first hospitalizations for major mood disorders with comorbid substance use
    Minnai, Gian Paolo
    Tondo, Leonardo
    Salis, Piergiorgio
    Ghiani, Carmen
    Manfredi, Andrea
    Paluello, Michela M.
    Baethge, Christopher
    Baldessarini, Ross J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (03): : 319 - 326
  • [34] Reasons for substance use and vulnerability factors in patients with substance use disorder and anxiety or mood disorders
    Bizzarri, Jacopo V.
    Rucci, Paola
    Sbrana, Alfredo
    Gonnelli, Chiara
    Massei, Guido Jacopo
    Ravani, Laura
    Girelli, Massimo
    Dell'Osso, Liliana
    Cassano, Giovanni B.
    ADDICTIVE BEHAVIORS, 2007, 32 (02) : 384 - 391
  • [35] The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder
    Goldstein, Benjamin I.
    Levitt, Anthony J.
    BIPOLAR DISORDERS, 2008, 10 (01) : 67 - 78
  • [36] Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
    Krystal, John H.
    Tolin, David F.
    Sanacora, Gerard
    Castner, Stacy A.
    Williams, Graham V.
    Aikins, Deane E.
    Hoffman, Ralph E.
    D'Souza, D. Cyril
    DRUG DISCOVERY TODAY, 2009, 14 (13-14) : 690 - 697
  • [37] Gabapentin in comorbid anxiety and substance use
    Verduin, Marcia L.
    McKay, Scot
    Brady, Kathleen T.
    AMERICAN JOURNAL ON ADDICTIONS, 2007, 16 (02): : 142 - 143
  • [38] Age at Immigration to Canada and the Occurrence of Mood, Anxiety, and Substance Use Disorders
    Patterson, Beth
    Kyu, Hmwe Hmwe
    Georgiades, Katholiki
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (04): : 210 - 217
  • [39] Substance use and infant outcomes in pregnant women with mood and anxiety disorders
    Kelly, M. B.
    Cornelius, M. D.
    Wisner, K. L.
    NEUROTOXICOLOGY AND TERATOLOGY, 2007, 29 (03) : 396 - 396
  • [40] Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study
    de Graaf, R
    Bijl, RV
    ten Have, M
    Beekman, ATF
    Vollebergh, WAM
    JOURNAL OF AFFECTIVE DISORDERS, 2004, 82 (03) : 461 - 467
12345